Tuesday, February 24, 2009
Friday, January 30, 2009
Wednesday, December 10, 2008
Maximizing Progress: MIT Neurotechnology Ventures 2008 ~ Top Plans!
Maximizing Progress: MIT Neurotechnology Ventures 2008 ~ Top Plans!
Neurotech is a theme which embraces a broad array of issues and opportunities including: Neuroimaging, Neurology/Psychiatry Diagnosis, Rehabilitation, Neurosurgery, Neuropharmacology, Brain Stimulation, Prosthetics, Sensory and Motor Augmentation, Gaming, Learning, Neuroveterinary Solutions, Regenerative Neuromedicine, and more. I'm quite delighted by and proud of the teams which pulled together some bold and even excellent new venture proposals, including...
* Aivot ~ ePatch Cognitive Behavior Therapy to Quit Smoking
* NeuroExtend ~ Veterinary Longevity Neural Implant
* MindLight ~ Children's Autism Detection System
* Vibraint ~ Learning Assessment Systems
* BrainState ~ Image-Guided Stroke Rehabilitation
* Data Driven Diagnostics (D3) ~ MRI Tests for Depression
* StrokeDx ~ Stroke Diagnostic Imaging Systems
* iSight ~ Vision Recuperation Solutions
* Sight Beyond Sight ~ Retinal Implant Vision Systems
* PsychCSR ~ Voice-Pattern Call Center QC Systems
Monday, November 3, 2008
McGovern Institute funds collaborative neurotechnology projects - MIT News Office
McGovern Institute funds collaborative neurotechnology projects - MIT News Office
The McGovern Institute for Brain Research has announced six new funding awards to develop technologies aimed at accelerating neuroscience research and developing new therapeutic approaches for brain disorders. The new projects are on themes ranging from brain-machine interfaces to new genetic tools and brain imaging methods.
The awards are part of the McGovern Institute Neurotechnology (MINT) program, established in 2006 to promote collaborations between neuroscientists and researchers from other disciplines within and beyond MIT. "Neuroscience has always been driven by new technologies," explained Charles Jennings, the MINT program director. "We want to take advantage of the extraordinary range of technological expertise at MIT to develop new methods that could transform the field."
The MINT awards typically provide up to $100,000 for one year of seed funding to test innovative ideas that traditional funding sources rarely support, and to determine if they are worth pursuing further.
The McGovern Institute for Brain Research has announced six new funding awards to develop technologies aimed at accelerating neuroscience research and developing new therapeutic approaches for brain disorders. The new projects are on themes ranging from brain-machine interfaces to new genetic tools and brain imaging methods.
The awards are part of the McGovern Institute Neurotechnology (MINT) program, established in 2006 to promote collaborations between neuroscientists and researchers from other disciplines within and beyond MIT. "Neuroscience has always been driven by new technologies," explained Charles Jennings, the MINT program director. "We want to take advantage of the extraordinary range of technological expertise at MIT to develop new methods that could transform the field."
The MINT awards typically provide up to $100,000 for one year of seed funding to test innovative ideas that traditional funding sources rarely support, and to determine if they are worth pursuing further.
Saturday, October 11, 2008
November 12, 2008 event
November 12, 2008 Innovation Series
Neuroscience Drug Discovery and Development:
The Route to Disease-Modifying Therapies
Program Description:
Disorders of the brain, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and psychiatric diseases such as schizophrenia and depression, pose some of the hardest challenges for the biopharmaceutical industry. The disease burden from brain disorders is enormous, and the commercial potential is correspondingly attractive to industry and its investors. However, complex pathophysiology, poor preclinical models, a lack of reliable biomarkers and expensive clinical trials all impede development of new therapies. Join us for a discussion of how the biopharmaceutical industry is addressing these challenges, with guest speakers from the cutting edge of neuroscience drug discovery.
Neuroscience Drug Discovery and Development:
The Route to Disease-Modifying Therapies
Program Description:
Disorders of the brain, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and psychiatric diseases such as schizophrenia and depression, pose some of the hardest challenges for the biopharmaceutical industry. The disease burden from brain disorders is enormous, and the commercial potential is correspondingly attractive to industry and its investors. However, complex pathophysiology, poor preclinical models, a lack of reliable biomarkers and expensive clinical trials all impede development of new therapies. Join us for a discussion of how the biopharmaceutical industry is addressing these challenges, with guest speakers from the cutting edge of neuroscience drug discovery.
Monday, July 14, 2008
Neurotechnology @ MIT & Beyond - An Enormous Emerging Research & Venture Domain
Neurotechnology @ MIT and Beyond ~ An Enormous Emerging Research and Venture Domain:
Joost Bonsen and I are co-organizing another Neurotech@MIT gathering this Tuesday night July 15th 2008, from 7-9pm. This informal evening of drinks, brainstorming, and conversation with fellow inventive and entrepreneurial friends will be at the Royal East over dinner. The Royal East Restaurant is at 792 Main St. Cambridge, MA. We each chip in to split the cost.
This Fall 2008, together with Ed Boyden and Rutledge Ellis-Behnke, Joost is co-teaching Neurotechnology Ventures, an Institute-wide elective projects-course at MIT on the challenges of envisioning, planning, and building startups to bring neuroengineering innovations to the world..."
Joost Bonsen and I are co-organizing another Neurotech@MIT gathering this Tuesday night July 15th 2008, from 7-9pm. This informal evening of drinks, brainstorming, and conversation with fellow inventive and entrepreneurial friends will be at the Royal East over dinner. The Royal East Restaurant is at 792 Main St. Cambridge, MA. We each chip in to split the cost.
This Fall 2008, together with Ed Boyden and Rutledge Ellis-Behnke, Joost is co-teaching Neurotechnology Ventures, an Institute-wide elective projects-course at MIT on the challenges of envisioning, planning, and building startups to bring neuroengineering innovations to the world..."
Friday, May 30, 2008
Upcoming Event - June 4th
From Paul Pyzowski:
The Massachusetts Medical Device Group is having a forum on the future of neuroscience and neurotech next Wednesday (June 4) in Waltham. I am moderating a panel that includes Charles Jennings from the McGovern as well as a practicing neurosurgeon and a neurotech entrepreneur.
Event link is here:
http://web.memberclicks.com/mc/community/eventdetails.do?eventId=131733&orgId=meg
MDG link is here:
http://www.meddevgroup.org/
The Massachusetts Medical Device Group is having a forum on the future of neuroscience and neurotech next Wednesday (June 4) in Waltham. I am moderating a panel that includes Charles Jennings from the McGovern as well as a practicing neurosurgeon and a neurotech entrepreneur.
Event link is here:
http://web.memberclicks.com/mc/community/eventdetails.do?eventId=131733&orgId=meg
MDG link is here:
http://www.meddevgroup.org/
Subscribe to:
Posts (Atom)
Posts
